Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 10:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 3,553 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fluids Clear all

Conditions: Blood Clots, Vascular Disease, Embolism Thrombosis, Cardiovascular Diseases, Lung Diseases
Interventions: Versus™ Endovascular Pulmonary Artery Drug Delivery Catheter; Device
Lead sponsor: Liquet Medical Inc.; Industry
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Alpha1-antitrypsin Deficiency
Interventions: GLASSIA; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 17
States / cities: Tucson, Arizona • Los Angeles, California • Sacramento, California + 13 more

Conditions: Fluid Overload, POCUS, Lung Ultrasound, Volume Status
Interventions: point-of-care ultrasound (POCUS), specifically lung ultrasound (LUS), Modified Medical Research Council (mMRC) Dyspnea scale, Physical Exam; Device · Other
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Acute Renal Failure (ARF), Acute Kidney Injury (AKI), Fluid Overload in Dialysis Patients
Interventions: Prismaflex HF20; Device
Lead sponsor: Vantive Health LLC; Industry
Eligibility: Not listed
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 5
States / cities: Birmingham, Alabama • Palo Alto, California • Chicago, Illinois + 2 more

Conditions: Bubbles in Colon at Time of Colonoscopy
Interventions: simethicone; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Critical Illness, Pediatrics, General Surgery, Fluid Therapy, Wounds and Injuries
Interventions: Balanced crystalloid solution volume administration, Packed Erythrocytes Units, Blood Product Unit volume, Plasma volume, Platelets volume; Other
Lead sponsor: Columbia University; Other
Eligibility: 6 Months to 15 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 4
States / cities: Buffalo, New York • New York, New York • Rochester, New York + 1 more

Conditions: Atopic Dermatitis
Interventions: Caffeine, Metoprolol, Midazolam, Warfarin, Vitamin K, Omeprazole, Rocatinlimab; Dietary Supplement · Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 7
States / cities: North Hollywood, California • DeLand, Florida • Hialeah, Florida + 4 more

Conditions: Kaposiform Hemangioendotheliomas, Tufted Angioma, Capillary Venous Lymphatic Malformation, Venous Lymphatic Malformation, Microcystic Lymphatic Malformation, Mucocutaneous Lymphangiomatosis and Thrombocytopenia, Capillary Lymphatic Arterial Venous Malformations, PTEN Overgrowth Syndrome With Vascular Anomaly, Lymphangiectasia Syndromes
Interventions: sirolimus; Drug
Lead sponsor: Denise Martin Adams; Other
Eligibility: Up to 31 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2020
U.S. locations: 2
States / cities: Boston, Massachusetts • Cincinnati, Ohio

Conditions: Muscle Damage, Strength Recovery, Perceived Recovery, Perceived Muscle Soreness, Physical Performance, Muscle Recovery
Interventions: proprietary post workout recovery supplement, Control placebo; Dietary Supplement
Lead sponsor: Applied Science & Performance Institute; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Nicotine E-Cigarette Use
Interventions: Water Concentration 1, Water Concentration 2, Water Concentration 3, Water Concentration 4; Other
Lead sponsor: Yale University; Other
Eligibility: 21 Years and older
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Skin Wrinkles on Face and Neck Areas
Interventions: Activation Mist; Other
Lead sponsor: California Allergy and Asthma Medical Group, Inc.; Other
Eligibility: 30 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Intracerebral Hemorrhage, Intracerebral Haemorrhage, Intraventricular Hemorrhage, Stroke, Cerebrovascular Disease
Interventions: Reversal of Oral anticoagulation within 30 minutes, Early intensive blood pressure lowering, Treatment of pyrexia, Hyperglycemia treatment, Do-not-resuscitate (DNR) or withdrawal of care, Referral to Intensive Care, Referral to Neurosurgery, Repeat brain imaging, Standard care; Other · Diagnostic Test
Lead sponsor: Region Skane; Other
Eligibility: 18 Years and older
Enrollment: 3,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Compartment Syndrome
Interventions: ECSPRESS catheter with active vacuum; Device
Lead sponsor: Twin Star Medical, Inc.; Industry
Eligibility: 18 Years to 44 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Baseline, Hemodilution
Interventions: Not listed
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Human Immunodeficiency Virus (HIV)
Interventions: Radiolabeled autologous seminal fluid, Radiolabeled Normosol-R; Biological
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years and older · Male only
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Wounds and Injuries, Multiple Trauma, Disorder of Fluid Balance
Interventions: Plasmalyte A, Normal Saline; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Healthy
Interventions: Tetrodotoxin, placebo; Drug
Lead sponsor: Wex Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2011
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Urinary Bladder, Overactive
Interventions: Solifenacin Succinate Suspension, Placebo, Urotherapy; Drug · Behavioral
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Shreveport, Louisiana • Albany, New York

Conditions: Obesity
Interventions: group sessions, sibutramine, orlistat, diethylpropion, Low Calorie Diet, Health One, Intensive Medical Combination Therapy for Obesity, Control Condition; Behavioral · Drug · Other
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 20 Years to 60 Years
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Eosinophilic Esophagitis
Interventions: Plasma and urine metabolomics; Diagnostic Test
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 2 Years to 18 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Ulcerative Colitis
Interventions: 75mg SHP647 (PF-00547659), 225mg SHP647 (PF-00547659); Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 66 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 29
States / cities: Scottsdale, Arizona • La Jolla, California • Orange, California + 26 more

Conditions: Thrombotic Thrombocytopenic Purpura
Interventions: Cyclosporine, Prednisone; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Small Fiber Neuropathy, Idiopathic Peripheral Neuropathy
Interventions: Intravenous immunoglobulin, 0.9% Sodium Chloride; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Autism Spectrum Disorder
Interventions: Wide-spectrum nutritional supplement, Placebo; Drug · Other
Lead sponsor: Rossignol Medical Center; Other
Eligibility: 2 Years to 17 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Phoenix, Arizona

Search by objective public record fields.

Single Center Post-Market Study of Thrombolytic Therapy Using the Versus™ Catheter

GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study

Concordance and Discordance in the Assessment of Volume Status in Home Dialysis Patients: A Comparison of Modified Medical Research Council Dyspnea Scale, Physical Exam, and Point of Care Ultrasound (POCUS)

Retrospective Analysis of Prismaflex HF20 Set Versus ppCRRT Registry

The Effects of Moviprep With Simethicone on Colonic Bubbles

Effect of Giving Reduced Fluid in Children After Trauma

Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis

Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies

The Effects of Liquid IV's Multi-Ingredient Recovery Supplement on Muscle Recovery Following Exercise

Water Content in E-Liquids

Study to Determine Effectiveness of Activation Mist on Facial Skin Wrinkles

International Care Bundle Evaluation in Cerebral Hemorrhage Research

Double Blinded, Randomized Clinical Trial of the Twin Star ECSPRESS Monitoring System for the Reduction of the Incidence of Fasciotomy

Performance of Non-Invasive Monitors During ANH

Effect of Seminal Fluid on the Colon Wall; Implications for HIV Transmission

Normal Saline Versus Plasmalyte in Initial Resuscitation of Trauma Patients

Comparison Study of Liquid and Lyophilized Formulations of Subcutaneous Tetrodotoxin (TTX) in Healthy Volunteers

A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug

LOSS- Louisiana Obese Subjects Study

Metabolomics for Biomarker Discovery in Children With EoE

Long-Term Safety Of PF-00547659 In Ulcerative Colitis

Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP)

IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3

Effect of a Wide Spectrum Nutritional Supplement on Mitochondrial Function in Children With Autism Spectrum Disorder